Stock listing
gettex:YB4P Savara, Inc. Aktie
German listing (gettex) of Savara, Inc. · home listing NASDAQ:SVRA
Follow Savara, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:SVRA
$4.26 USD -0.46 (-9.7%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SVRA
- Day range
- $4.00 – $4.52 USDNov 20, 2026
- Volume
- 17.01M sharesNov 20, 2026
- Market cap
- $939.9M USDAt the close on Nov 20, 2026 · price × 220.6M shares outstanding
- 52-week range
- $4.00 – $7.01 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $12.85M USDMedian day 2.18M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:SVRA · Home | $4.26 USD | -0.46 (-9.7%) | 17,013,104 | $4.18 | $4.52 | $4.00 | $4.72 | Close on Nov 20, 2026 |
| Frankfurt:YB4P | €3.917 EUR | -0.583 (-13.0%) | — | €4.666 | €4.666 | €3.917 | €4.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SVRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $4.26 | -0.46 | -9.7% | $4.18 | $4.52 | $4.00 | 17,013,104 | |
| $4.72 | +0.24 | +5.4% | $4.60 | $4.87 | $4.55 | 5,510,085 | |
| $4.48 | +0.015 | +0.3% | $4.60 | $4.60 | $4.35 | 3,790,035 | |
| $4.465 | -0.175 | -3.8% | $4.70 | $4.735 | $4.40 | 2,769,865 | |
| $4.64 | -0.08 | -1.7% | $4.80 | $4.84 | $4.58 | 3,229,455 | |
| $4.72 | -0.27 | -5.4% | $5.03 | $5.03 | $4.67 | 4,292,661 | |
| $4.99 | +0.07 | +1.4% | $4.99 | $5.205 | $4.92 | 9,260,244 | |
| $4.92 | -0.13 | -2.6% | $4.86 | $5.15 | $4.84 | 1,728,042 | |
| $5.05 | +0.22 | +4.6% | $4.943 | $5.065 | $4.76 | 2,399,378 | |
| $4.83 | +0.45 | +10.3% | $4.46 | $4.89 | $4.41 | 2,216,685 | |
| $4.38 | -0.28 | -6.0% | $4.63 | $4.636 | $4.325 | 2,891,977 | |
| $4.66 | -0.09 | -1.9% | $4.84 | $4.88 | $4.46 | 3,559,075 | |
| $4.75 | +0.02 | +0.4% | $4.78 | $4.88 | $4.655 | 2,110,362 | |
| $4.73 | -0.09 | -1.9% | $4.83 | $4.91 | $4.67 | 1,775,756 | |
| $4.82 | -0.13 | -2.6% | $4.936 | $4.97 | $4.75 | 1,409,437 | |
| $4.95 | -0.07 | -1.4% | $5.05 | $5.13 | $4.915 | 1,740,801 | |
| $5.02 | +0.16 | +3.3% | $4.82 | $5.05 | $4.775 | 1,785,855 | |
| $4.86 | +0.34 | +7.5% | $4.49 | $4.905 | $4.45 | 3,590,010 | |
| $4.52 | +0.30 | +7.1% | $4.30 | $4.535 | $4.216 | 3,441,276 | |
| $4.22 | -0.32 | -7.0% | $4.52 | $4.58 | $4.13 | 2,827,900 | |
| $4.54 | -0.13 | -2.8% | $4.65 | $4.75 | $4.45 | 2,709,700 | |
| $4.67 | -0.09 | -1.9% | $4.79 | $4.945 | $4.66 | 2,086,100 | |
| $4.76 | +0.13 | +2.8% | $4.64 | $4.99 | $4.60 | 4,417,400 | |
| $4.63 | +0.18 | +4.0% | $4.53 | $4.705 | $4.495 | 1,560,300 | |
| $4.45 | -0.29 | -6.1% | $4.75 | $4.77 | $4.44 | 2,235,000 | |
| $4.74 | -0.02 | -0.4% | $4.76 | $4.90 | $4.72 | 1,690,900 | |
| $4.76 | -0.02 | -0.4% | $4.71 | $4.82 | $4.65 | 2,574,300 | |
| $4.78 | -0.06 | -1.2% | $4.84 | $5.02 | $4.76 | 3,742,100 | |
| $4.84 | -0.08 | -1.6% | $4.93 | $5.00 | $4.81 | 1,306,700 | |
| $4.92 | +0.09 | +1.9% | $4.82 | $4.975 | $4.81 | 1,529,100 | |
| $4.83 | -0.05 | -1.0% | $4.85 | $4.92 | $4.635 | 2,514,600 | |
| $4.88 | +0.23 | +4.9% | $4.74 | $5.05 | $4.69 | 2,414,900 | |
| $4.65 | -0.13 | -2.7% | $4.82 | $4.84 | $4.60 | 2,289,400 | |
| $4.78 | -0.03 | -0.6% | $4.85 | $4.915 | $4.71 | 2,862,300 | |
| $4.81 | -0.235 | -4.7% | $5.10 | $5.16 | $4.765 | 2,653,300 | |
| $5.045 | -0.115 | -2.2% | $5.15 | $5.24 | $5.03 | 2,549,600 | |
| $5.16 | +0.08 | +1.6% | $5.15 | $5.24 | $5.05 | 6,051,300 | |
| $5.08 | +0.01 | +0.2% | $5.07 | $5.19 | $5.00 | 2,034,700 | |
| $5.07 | +0.07 | +1.4% | $4.97 | $5.155 | $4.86 | 4,371,000 | |
| $5.00 | -0.07 | -1.4% | $5.08 | $5.18 | $4.87 | 2,451,000 | |
| $5.07 | +0.07 | +1.4% | $5.03 | $5.085 | $4.884 | 2,499,200 | |
| $5.00 | -0.30 | -5.7% | $5.30 | $5.34 | $4.90 | 3,352,900 | |
| $5.30 | -0.15 | -2.8% | $5.52 | $5.525 | $5.29 | 1,412,900 | |
| $5.45 | +0.08 | +1.5% | $5.44 | $5.51 | $5.36 | 1,311,900 | |
| $5.37 | -0.05 | -0.9% | $5.42 | $5.47 | $5.305 | 2,181,900 | |
| $5.42 | +0.29 | +5.7% | $5.23 | $5.465 | $5.22 | 1,228,700 | |
| $5.13 | -0.13 | -2.5% | $5.29 | $5.351 | $5.105 | 1,127,000 | |
| $5.26 | -0.08 | -1.5% | $5.33 | $5.34 | $5.175 | 1,301,400 | |
| $5.34 | +0.04 | +0.8% | $5.33 | $5.43 | $5.28 | 1,310,100 | |
| $5.30 | -0.02 | -0.4% | $5.38 | $5.395 | $5.27 | 1,063,700 | |
| $5.32 | -0.095 | -1.8% | $5.34 | $5.46 | $5.24 | 1,525,400 | |
| $5.415 | -0.115 | -2.1% | $5.48 | $5.57 | $5.37 | 1,095,500 | |
| $5.53 | +0.16 | +3.0% | $5.27 | $5.63 | $5.26 | 1,660,800 | |
| $5.37 | 0.00 | 0.0% | $5.32 | $5.39 | $5.31 | 625,200 | |
| $5.37 | -0.09 | -1.6% | $5.52 | $5.52 | $5.29 | 1,240,400 | |
| $5.46 | +0.11 | +2.1% | $5.47 | $5.56 | $5.365 | 1,216,800 | |
| $5.35 | -0.04 | -0.7% | $5.32 | $5.405 | $5.29 | 1,042,100 | |
| $5.39 | +0.13 | +2.5% | $5.25 | $5.44 | $5.21 | 1,958,700 | |
| $5.26 | -0.23 | -4.2% | $5.48 | $5.51 | $5.25 | 1,336,300 | |
| $5.49 | -0.12 | -2.1% | $5.59 | $5.66 | $5.485 | 1,595,300 | |
| $5.61 | +0.01 | +0.2% | $5.58 | $5.68 | $5.51 | 1,529,800 | |
| $5.60 | +0.04 | +0.7% | $5.69 | $5.72 | $5.52 | 1,608,654 | |
| $5.56 | -0.03 | -0.5% | $5.60 | $5.60 | $5.425 | 1,323,851 | |
| $5.59 | +0.10 | +1.8% | $5.54 | $5.64 | $5.50 | 3,035,200 | |
| $5.49 | -0.09 | -1.6% | $5.52 | $5.59 | $5.26 | 2,541,800 |
Splits
3 splits since 2000 · NASDAQ:SVRA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-70 | Consolidation | |
| 1-for-25 | Consolidation | |
| 1-for-1.99 | Consolidation |
- Ticker
- gettex:YB4P
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
Latest deck · Sep 6, 2026
Technical Presentation (September 2026)
Technical · 11 slides
Latest news
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
Nov 20, 2026
Closed $4.26 (-9.7%) on Nov 20, 2026
Savara Announces New Employment Inducement Grant
Nov 12, 2026
Closed $4.64 (-1.7%) on Nov 13, 2026
Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment
Oct 21, 2026
Closed $4.67 (-1.9%) on Oct 21, 2026
Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026
Oct 12, 2026
Closed $4.78 (-1.2%) on Oct 13, 2026
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP)
Aug 25, 2026
Closed $5.60 (+0.7%) on Aug 25, 2026
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Aug 24, 2026
Closed $5.60 (+0.7%) on Aug 25, 2026
Savara Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 11, 2026
Closed $5.70 (+2.3%) on Aug 12, 2026
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Jul 30, 2026
Closed $5.54 (+4.9%) on Jul 30, 2026
Savara Announces Chief Financial and Administrative Officer Transition
Jun 8, 2026
Closed $4.93 (-2.6%) on Jun 9, 2026
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Closed $5.09 (-2.3%) on May 28, 2026
Savara, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 158 in all · newest Nov 20, 2026 · oldest 2019
- Decks
- 66 decks · latest Sep 6, 2026
Where Savara, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:SVRA · Home listing | NASDAQ | United States | USD |
| Lang & Schwarz:A2DQ2B | Lang & Schwarz | Germany | EUR |
| LS Exchange:A2DQ2B | LS Exchange | Germany | EUR |
| gettex:YB4P · This page | gettex | Germany | EUR |
| Frankfurt:YB4P | Frankfurt | Germany | EUR |
| BOATS:SVRA | BOATS | United States | USD |
| Tradegate:YB4P | Tradegate | Germany | EUR |
| Dusseldorf:YB4P | Dusseldorf | Germany | EUR |
| Munich:YB4P | Munich | Germany | EUR |
| Stuttgart:YB4P | Stuttgart | Germany | EUR |
Valuation
Price/book 8.7× against a median of 2.4×: 8th lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $840.4M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 8.7×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 1.42
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Savara, Inc. · NASDAQ:SVRA | US$939.9M | US$840.4M | n/a | n/a | n/a | 8.7× | n/a | 0.3× | 1.42 |
| Omeros Corporation · NASDAQ:OMER | US$983.7M | US$920.3M | 10.0× | 12.4× | n/a | n/a | 132.3% | n/a | 1.64 |
| Everest Medicines Ltd. · HKEX:1952 | US$981.6M | US$1.00B | n/a | 2.8× | 183× | 1.3× | −2.2% | 0.4× | n/a |
| HBM Holdings Ltd. · HKEX:2142 | US$981.4M | US$711.6M | 10.7× | 4.5× | 8.6× | 2.4× | 57.8% | 0.2× | n/a |
| Peptron, Inc. · KRX:087010 | US$979.2M | US$942.2M | n/a | 211× | n/a | 10.2× | −342.2% | 0.2× | n/a |
| City Therapeutics, Inc. · NASDAQ:CTY | US$972.4M | US$802.8M | n/a | 59.2× | n/a | n/a | −431.4% | n/a | n/a |
| Seaport Therapeutics, Inc. · NASDAQ:SPTX | US$966.2M | US$675.8M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.72 |
| MoonLake Immunotherapeutics · NASDAQ:MLTX | US$942.1M | US$543.7M | n/a | n/a | n/a | 2.5× | n/a | 0.3× | 1.32 |
| Metis TechBio Co., Ltd. Class H · HKEX:7666 | US$918.2M | US$486.7M | n/a | 222× | n/a | 2.0× | −373.2% | 0.0× | n/a |
| InventisBio, Co., Ltd. Class A · SSE:688382 | US$899.5M | US$714.3M | n/a | 67.0× | n/a | 4.6× | −533.7% | 0.0× | n/a |
| InnoCare Pharma Ltd. Class A · SSE:688428 | US$896.7M | −US$209.5M | 9.3× | −0.6× | −2.3× | 0.8× | 27.1% | 0.1× | n/a |
| Median of the others | US$969.3M | US$712.9M | 10.0× | 35.8× | 8.6× | 2.4× | −172.2% | 0.2× | 1.32 |
Forecasts
6 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 11.06 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.62 · 5 analysts
- Revenue, year to Dec 2026
- 880K · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Matt Pauls | Chair of the Board of Directors, Chief Executive Officer |
| Rob Lutz | Chief Operating and Financial Officer |
| Kate McCabe | Chief Legal Officer |
| Brian Robinson | EVP, Global Medical Affairs |
| Charles LaPree | EVP, Head of Global Regulatory Affairs |
| Sid Advant | EVP, Global Technical Operations |
| Anne Erickson | Chief Business and Corporate Affairs Officer |
| Braden Parker | Chief Commercial Officer |
| Megan Carpenter | Chief People Officer |
| Yasmine Wasfi | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Matt Pauls | Chair of the Board of Directors, Chief Executive Officer |
| Ali Ataya | M.D., MBA, ATSF |
| An van Es-Johansson | Audit Committee, Compensation Committee |
| Bruce Trapnell | M.D. |
| Cormac McCarthy | M.D., Ph.D., FRCPI |
| David A. Ramsay | Audit Committee (Chair), Nominating & Governance Committee |
| Francesco Bonella | M.D., Ph.D |
| Ilaria Campo | Ph.D. |
| Joe McCracken | Nominating & Governance Committee (Chair), Compensation Committee |
| Maria Kokosi | M.D. |
| Nevan Elam | Compensation Committee (Chair), Nominating & Governance Committee |
| Richard J. Hawkins | Audit Committee |
| Yoshikazu Inoue | M.D., Ph.D. |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −2.6% |
| Q2 2026 | Aug 11, 2026 · After close | +2.3% |
| Q1 2026 | May 7, 2026 | −0.8% |
| Q4 2025 | Mar 13, 2026 · Before open | −1.3% |
| Q3 2025 | Nov 12, 2025 · After close | +3.4% |
| Q2 2025 | Aug 13, 2025 · Before open | +4.7% |
| Q1 2025 | May 7, 2025 · Before open | +2.0% |
| Q4 2024 | Mar 27, 2025 · Before open | +3.0% |
| Q3 2024 | Nov 12, 2024 · Before open | −5.9% |
| Q2 2024 | Aug 12, 2024 · After close | +1.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | −8.2% |
| Q4 2023 | Mar 7, 2024 · After close | −5.2% |
| Q3 2023 | Nov 9, 2023 · After close | +1.8% |
| Q2 2023 | Aug 10, 2023 · After close | +1.0% |
| Q1 2023 | May 15, 2023 · Before open | −0.5% |
| Q4 2022 | Mar 30, 2023 · After close | −4.4% |
| Q3 2022 | Nov 10, 2022 · After close | +2.6% |
| Q2 2022 | Aug 11, 2022 · After close | +0.6% |
| Q1 2022 | May 11, 2022 · After close | +1.8% |
| Q4 2021 | Mar 30, 2022 · After close | +3.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 11 slides | Sep 6, 2026 |
| American Thoracic Society (ATS) 2026 International Conference | Conference | 9 slides | May 18, 2026 |
| Investor Presentation (January 2026) | Investor deck | 47 slides | Jan 9, 2026 |
| Investor Presentation (October 2025) | Investor deck | 15 slides | Oct 29, 2025 |
| Investor Presentation (September 2025) | Investor deck | 48 slides | Sep 2, 2025 |
| Investor Presentation (May 2025) | Investor deck | 47 slides | May 2025 |
| Investor Presentation (March 2025) | Investor deck | 47 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 43 slides | January 2025 |
| Investor Presentation (December 2024) | Investor deck | 34 slides | Dec 20, 2024 |
| Technical Presentation (2024) | Technical | 15 slides | Dec 5, 2024 |
Show 50 decks
This page holds 50 of 66 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$149.5M raised Use of proceeds: Accelerate investment in preparing for potential commercialization of MOLBREEVI | Nov 12, 2025 |
| Royalty on U.S. net sales of MOLBREEVI Announced: US$75M Buyers: RTW ($75 million royalty funding; tiered single digit percentage of annual U.S. net sales of MOLBREEVI, subject to a cap) Use of proceeds: Support the potential U.S. launch and commercialization of MOLBREEVI in autoimmune PAP | Oct 29, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.00K | 257.0K | 0 | 0 | 0 | 400.0K |
| Cost of revenue | 245.0K | 78.0M | 44.3M | 27.9M | 29.0M | 35.0M | 38.8M | 526.0K | 363.0K | 8.18M |
| Gross profit | -245.0K | -78.0M | -44.3M | -27.9M | -29.0M | -34.8M | -38.8M | -526.0K | -363.0K | 400.0K |
| Research and development | 81.4M | 78.0M | 44.3M | 27.9M | 29.0M | 35.0M | 38.8M | 37.2M | 18.5M | 8.18M |
| Selling, general and administrative | 42.1M | 25.0M | 15.7M | 10.9M | 12.3M | 12.0M | 12.9M | 10.7M | 11.1M | 9.34M |
| Operating income | -123.5M | -103.2M | -60.0M | -38.8M | -41.5M | -49.3M | -79.0M | -70.0M | -30.0M | -10.9M |
| Depreciation and amortization | 87.0K | 130.0K | 77.0K | 31.0K | 136.0K | 255.0K | 1.01M | 526.0K | 363.0K | 99.0K |
| EBITDA | -123.5M | -103.1M | -59.9M | -38.8M | -41.3M | -49.0M | -78.0M | -69.5M | -29.6M | -10.8M |
| Interest expense | 88.0K | 2.28M | 1.48M | 70.0K | 11.0K | 1.16M | 452.0K | |||
| Income before tax | -118.8M | -95.9M | -54.7M | -38.1M | -43.0M | -49.6M | -78.2M | -68.6M | -33.4M | -11.3M |
| Income tax | 0 | 9.00K | 797.0K | 796.0K | 2.28M | 1.48M | 26.9M | -7.06M | -3.63M | -357.0K |
| Net income | -118.8M | -95.9M | -54.7M | -38.1M | -43.0M | -49.6M | -78.2M | -61.5M | -29.8M | -10.9M |
| Earnings per share, basic | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -1.95 | -1.85 | -1.76 | -5.62 |
| Earnings per share, diluted | -0.53 | -0.48 | -0.33 | -0.25 | -0.32 | -0.84 | -1.95 | -1.85 | -1.76 | -5.62 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 33.2M | 15.1M | 26.6M | 52.1M | 34.0M | 22.9M | 49.8M | 24.3M | 22.1M | 13.4M |
| Short-term investments | 202.5M | 181.2M | 135.7M | 73.8M | 127.2M | 59.3M | 72.0M | 86.5M | 72.2M | 0 |
| Receivables | 1.25M | 1.04M | 1.00M | 954.0K | 1.14M | 1.70M | 1.62M | 1.68M | 1.03M | 868.0K |
| Inventory | 1 | 2.05M | -1.14M | -1.70M | -1.62M | 2.48M | 337.0K | |||
| Current assets | 241.6M | 202.1M | 165.9M | 129.0M | 165.0M | 85.1M | 124.1M | 113.3M | 97.9M | 14.6M |
| Property, plant and equipment | 100.0K | 165.0K | 270.0K | 51.0K | 73.0K | 156.0K | 352.0K | 522.0K | 925.0K | 793.0K |
| Goodwill | 0 | 0 | 26.9M | 27.1M | 3.05M | |||||
| Total assets | 253.4M | 212.9M | 177.6M | 139.8M | 176.6M | 97.7M | 136.2M | 152.3M | 159.6M | 28.9M |
| Accounts payable | 5.76M | 4.54M | 3.50M | 1.33M | 1.44M | 2.60M | 3.41M | 3.88M | 2.78M | 536.0K |
| Current liabilities | 20.4M | 14.7M | 10.6M | 5.87M | 14.7M | 8.17M | 10.9M | 7.25M | 6.01M | 3.46M |
| Long-term debt | 29.9M | 26.6M | 26.3M | 26.1M | 17.3M | 25.1M | 23.1M | 24.5M | 14.8M | 2.29M |
| Total debt | 29.9M | 26.6M | 26.3M | 26.1M | 25.7M | 25.1M | 25.6M | 24.6M | 15.3M | 4.47M |
| Total liabilities | 50.3M | 41.4M | 37.2M | 32.0M | 32.1M | 33.4M | 34.5M | 44.1M | 40.3M | 20.9M |
| Shareholders' equity | 203.1M | 171.4M | 140.4M | 107.8M | 144.5M | 64.4M | 101.7M | 108.2M | 119.3M | -35.9M |
| Shares outstanding | 204.6M | 172.4M | 138.1M | 114.0M | 114.0M | 54.2M | 50.8M | 35.1M | 30.5M | 3.16M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -101.0M | -89.1M | -51.1M | -34.6M | -40.1M | -39.8M | -45.1M | -39.3M | -28.2M | -8.37M |
| Capital spending | -22.0K | -25.0K | -296.0K | -9.00K | -57.0K | -47.0K | -148.0K | -141.0K | -495.0K | -8.00K |
| Free cash flow | -101.1M | -89.1M | -51.4M | -34.6M | -40.1M | -39.9M | -45.3M | -39.4M | -28.7M | -8.38M |
| Cash from investing | -18.4M | -39.9M | -57.1M | 52.6M | -69.5M | 9.05M | 15.7M | -13.6M | -69.1M | -8.00K |
| Cash from financing | 137.8M | 117.6M | 82.8M | 87.0K | 120.8M | 3.69M | 54.9M | 55.2M | 106.1M | 5.12M |
| Dividends paid | -2.12M | 0 | 0 | |||||||
| Share buybacks | -5.14M | -995.0K | -1.21M | -3.00K | -78.0K | 2.12M | 54.9M | 46.4M | 91.3M | 19.3M |
| Change in cash | 18.1M | -11.5M | -25.5M | 18.1M | 11.1M | -26.9M | 25.5M | 2.18M | 8.75M | -3.31M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 25, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 8, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 10, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 13, 2026 | Material contract | SEC |
| 10-K · Annual report | Mar 13, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 27, 2026 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 5, 2025 | Big-stake notice | SEC |
| 424B5 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 29, 2025 | Offer document | SEC |
| 8-K · Current report | Oct 29, 2025 | Material contract | SEC |
| 4 · Change in ownership | Oct 22, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 8, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 8-K · Current report | May 27, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Apr 25, 2025 | Annual report | SEC |
| 4 · Change in ownership | Apr 1, 2025 | Insider trade | SEC |
| 8-K · Current report | Mar 31, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 27, 2025 | Big-stake notice | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 26, 2025 | Material contract | SEC |
| 3 · Initial statement of ownership | Mar 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2025 | Management or board change | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Nov 27, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 6, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 22, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Oct 1, 2024 | Offer document | SEC |
| 4 · Change in ownership | Sep 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 27, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Jul 26, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jul 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jun 28, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jun 28, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 26, 2024 | Current report | SEC |
| 8-K/A · Current report, amended | Jun 10, 2024 | Management or board change | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| EFFECT · Notice that a registration is effective | May 22, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 23, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 12, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 12, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 12, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Mar 29, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 7, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 7, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 16, 2024 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 31, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 25, 2024 | Management or board change | SEC |
| 8-K · Current report | Jan 5, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 29, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 28, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 28, 2023 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 28, 2023 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 26, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jul 25, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 19, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jul 13, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Jul 13, 2023 | Offer document | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jun 16, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 9, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jun 8, 2023 | Current report | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Mar 30, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 8-K · Current report | Mar 2, 2023 | Material contract | SEC |
| 4 · Change in ownership | Feb 28, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 22, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Feb 14, 2023 | Management or board change | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Savara, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 220,623,511
- Fully diluted
- 220,690,511
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 220,623,511 | Nov 9, 2026 |
| Options and RSUs | 67,000 | Nov 10, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$4.92 · expire about Nov 2036 |
| RSUs · expiry not stated |
| PSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 9, 2026 | 220,623,511 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ted W Love Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past); Oruka Therapeutics, Inc. (Director · Mar 7, 2006 – Feb 5, 2010 · Past) | Director · Sep 5, 2012 – Jun 19, 2013 · Past |
| Alexander J Denner Other companies: Ironwood Pharmaceuticals, Inc. (Director · Since at least Nov 9, 2020); Bioverativ Inc (Director · Jan 10, 2017 – Mar 8, 2018 · Past); The Medicines Company (Director · Feb 2, 2016 – Jan 6, 2020 · Past); Ariad Pharmaceuticals Inc (Director · Feb 20, 2014 – Feb 16, 2017 · Past); VIVUS Inc (Director · Aug 14, 2013 – Oct 30, 2015 · Past); Biogen Inc. (Director · Jun 10, 2009 – Jun 15, 2022 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Aug 8, 2012 · Past); Viskase Holdings, Inc. (Director · May 21, 2009 – Jan 2, 2013 · Past) | Director · Oct 26, 2006 – Oct 16, 2009 · Past |
| Matt Pauls Other companies: Palvella Therapeutics, Inc. (Director · Since at least Jun 29, 2026); Pelthos Therapeutics Inc. (Director · Since at least Jul 1, 2025); Soleno Therapeutics, Inc. (Director · Since at least Aug 15, 2023); Egalet Corporation (Director · Jan 31, 2019 – May 20, 2020 · Past); Strongbridge Biopharma plc (President & CEO, Director · Jan 1, 2018 – Feb 20, 2019 · Past) | CHIEF EXECUTIVE OFFICER, Director · Since at least Oct 29, 2015 |
| Brandi Roberts Other companies: Definium Therapeutics, Inc. (Chief Financial Officer · Since at least Jun 2, 2025); TFF Pharmaceuticals Inc (Director · Mar 25, 2022 – Jul 3, 2024 · Past); Longboard Pharmaceuticals Inc (Executive VP and CFO · Mar 11, 2021 – Dec 2, 2024 · Past); Lineage Cell Therapeutics, Inc. (CFO & SVP Finance · Jan 7, 2019 – Mar 17, 2020 · Past) | Chief Financial Officer & SVP · Jun 19, 2013 – Jan 20, 2017 · Past |
| Santosh Vetticaden Other companies: Depomed Inc (SVP, Chief Medical Officer *** · Oct 16, 2017 – Feb 6, 2018 · Past); INSYS Therapeutics Inc (Interim CEO and CMO · Jan 9, 2017 – Feb 21, 2017 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Medical Officer · Dec 2, 2008 – Dec 30, 2011 · Past); Maxygen Inc (Chief Medical Officer · Feb 13, 2007 – Jul 1, 2008 · Past) | Chief Medical Officer & SVP · Sep 5, 2012 – Jun 19, 2014 · Past |
| Joe McCracken Other companies: Lumos Pharma Inc (Director · Mar 23, 2020 – Dec 12, 2024 · Past); Kindred Biosciences Inc (Director · Apr 20, 2018 – Aug 27, 2021 · Past); Nexvet Biopharma plc (Director · Feb 4, 2015 – Jul 31, 2017 · Past) | Nominating & Governance Committee (Chair), Compensation Committee · Since at least Apr 27, 2017 |
| Michael M Goldberg Other companies: Echo Therapeutics Inc (Director · Feb 28, 2014 – Mar 21, 2017 · Past); Urigen Pharmaceuticals Inc (Director · Jun 11, 2009 – Aug 13, 2009 · Past); Emisphere Technologies Inc (Director · Dec 19, 2006 – Aug 22, 2007 · Past) | Director · Jun 2, 2006 – Jun 30, 2010 · Past |
| Richard J. Hawkins Other companies: Plus Therapeutics, Inc. (Director · Since at least Jun 25, 2020); Lumos Pharma Inc (Chief Executive Officer, Director · Mar 18, 2020 – Dec 12, 2024 · Past); SciClone Pharmaceuticals Inc (Director · Oct 13, 2017 – Oct 13, 2017 · Past) | Audit Committee · Since at least Dec 17, 2017 |
| An van Es-Johansson Other companies: Plus Therapeutics, Inc. (Director · Since at least Jan 1, 2020); Lumos Pharma Inc (Director · Feb 16, 2021 – Dec 12, 2024 · Past) | Audit Committee, Compensation Committee · Since at least Dec 3, 2019 |
| David Ramsay Other companies: Halozyme Therapeutics, Inc. (President, Drug Delivery · Since at least Mar 23, 2026); La Jolla Pharmaceutical Co (Director · Oct 8, 2019 – Aug 22, 2022 · Past) | Director · Since at least Jun 19, 2019 |
All 47 people
| Person | Seat |
|---|---|
| Evan Levine Other companies: ProBility Media Corp. (Chief Executive Officer, Director · Nov 8, 2016 – Nov 30, 2018 · Past); Quantrx Biomedical (Director · Feb 6, 2007 – Feb 6, 2007 · Past) | CEO & President, Director · Apr 24, 2006 – Apr 15, 2008 · Past |
| Nevan Charles Elam Other companies: Rezolute, Inc. (Chief Executive Officer & Founder · Since at least Jan 31, 2013); Nektar Therapeutics (SVP & Head of Pulmonary Bus · Mar 10, 2006 – Feb 25, 2008 · Past) | Compensation Committee (Chair), Nominating & Governance Committee · Since at least Apr 27, 2017 |
| Ricky Sun Other companies: Annexon, Inc. (Director · Jul 23, 2020 – Jun 2, 2021 · Past); Arcutis Biotherapeutics, Inc. (Director · Jan 30, 2020 – Jun 9, 2021 · Past) | Director · Dec 24, 2019 – Dec 14, 2023 · Past |
| Robert Martin Emanuele Other companies: Artelo Biosciences, Inc. (Director · Since at least Jun 21, 2019); Avanir Pharmaceuticals Inc (V P, Business Development · May 25, 2006 – May 25, 2006 · Past) | Senior VP, Development · Apr 27, 2011 – Jan 4, 2016 · Past |
| Rob Lutz Other companies: iBio, Inc. (See Remarks · Mar 4, 2021 – Nov 11, 2022 · Past); Strongbridge Biopharma plc (Chief Financial Officer · Sep 3, 2019 – Feb 22, 2021 · Past) | Chief Operating and Financial Officer · Since at least Feb 13, 2023 |
| Badrul A Chowdhury Other companies: Kineta Inc. (Director · May 12, 2019 – Jun 29, 2020 · Past) | CHIEF MEDICAL OFFICER · Nov 27, 2019 – Dec 14, 2021 · Past |
| Gregory Gorgas Other companies: Artelo Biosciences, Inc. (President & Chief Executive Officer · Since at least Jun 21, 2019) | Senior VP, Commercial · Jul 21, 2011 – Jan 4, 2016 · Past |
| Jack Lief Other companies: Arena Pharmaceuticals Inc (President and CEO, Director · Dec 30, 2005 – Mar 3, 2015 · Past) | Director · Sep 22, 2006 – Jun 11, 2015 · Past |
| Joachim PH Schupp Other companies: Harrow, Inc. (CHIEF MEDICAL OFFICER · Oct 12, 2009 – Apr 1, 2013 · Past) | VP, Medical Affairs · Aug 15, 2006 – Mar 31, 2008 · Past |
| Lewis Shuster Other companies: Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past) | Director · Apr 8, 2011 – Jun 11, 2015 · Past |
| Mark Bagnall Other companies: Via Pharmaceuticals Inc (Director · Dec 17, 2007 – Dec 17, 2008 · Past) | CFO & Executive Vice President, Director · Jun 2, 2006 – Apr 3, 2008 · Past |
| Raymond Dennis Pratt Other companies: Rockwell Medical, Inc. (Chief Development Officer · Jun 14, 2013 – May 3, 2021 · Past) | Chief Medical Officer · Nov 10, 2022 – Dec 12, 2024 · Past |
| Ali Ataya | M.D., MBA, ATSF · Since at least Aug 18, 2025 |
| Anne Erickson | Chief Business and Corporate Affairs Officer · Since at least Mar 21, 2024 |
| Braden Parker | Chief Commercial Officer · Since at least Sep 24, 2024 |
| Brian Robinson | EVP, Global Medical Affairs · Since at least Nov 5, 2026 |
| Bruce Trapnell | M.D. · Since at least Oct 21, 2026 |
| Charles LaPree | EVP, Head of Global Regulatory Affairs · Since at least Nov 5, 2026 |
| Cormac McCarthy | M.D., Ph.D., FRCPI · Since at least Aug 25, 2026 |
| David L Lowrance | Chief Financial Officer · Since at least Apr 27, 2017 |
| Edwin L Parsley | Chief Medical Officer & SVP · Sep 1, 2014 – Jan 20, 2017 · Past |
| Francesco Bonella | M.D., Ph.D · Since at least Sep 29, 2025 |
| Ilaria Campo | Ph.D. · Since at least Aug 25, 2026 |
| Joan M Robbins | CSO, Sr. VP · Jan 31, 2006 – May 13, 2008 · Past |
| Kate McCabe | Chief Legal Officer · Since at least Jul 30, 2026 |
| Kathleen R McCabe | Chief Legal Officer · Since at least Mar 13, 2025 |
| Maria Kokosi | M.D. · Since at least Nov 4, 2026 |
| Mark E Erwin | SVP, Operations · Oct 20, 2008 – Jan 30, 2009 · Past |
| Mark Joseph Cantwell | VP, Research & Development · Feb 28, 2006 – Jan 12, 2007 · Past |
| Megan Carpenter | Chief People Officer · Since at least Nov 5, 2026 |
| M Ross Johnson | Director · Jun 2, 2006 – Dec 21, 2006 · Past |
| Robert N Neville | Chief Executive Officer, Director · Apr 27, 2017 – Dec 20, 2019 · Past |
| Shana Hood | General Counsel & VP · Jan 19, 2016 – Jan 20, 2017 · Past |
| Sid Advant | EVP, Global Technical Operations · Since at least Nov 5, 2026 |
| Yasmine Wasfi | Chief Medical Officer · Since at least Oct 17, 2025 |
| Yoshikazu Inoue | M.D., Ph.D. · Since at least Aug 25, 2026 |
| Yuri Pikover | Director · Apr 27, 2017 – Dec 13, 2018 · Past |
Log in to ask 6ix AI your own questions about Savara, Inc.